Biotech Tweets of the Week: Gilead Sciences and Orexigen

Not on twitter? (That should include some of you.)

Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.)

Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to catch you up (at least a little). In the video below, the duo discusses two recent tweets they found interesting.

In the first, ISI analyst Mark Schoenebaum points out that the P/E for Gilead Sciences (NASDAQ: GILD  ) has remained relatively unchanged despite the substantial run-up the company has experienced.

In the second tweet, Dan Loncar makes an observation that Orexigen (NASDAQ: OREX  ) says it's "highly confident" in an FDA approval for its obesity drug, but only "confident" in an approval by European regulators. The wording isn't particularly surprising given that its competitors -- VIVUS' (NASDAQ: VVUS  ) Qsymia and Arena Pharmaceuticals' (NASDAQ: ARNA  ) Belviq -- have gotten approved stateside, but not in Europe.

Biotech has nothing on this $14.4 trillion industry
Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.


Read/Post Comments (3) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 25, 2014, at 12:12 PM, marp11 wrote:

    OREX JUST REJECTED BY EU

    BELVIQ NEVER REJECTED APPLICATION PULLED BY ARNA

    WILL RESUBMIT AND WILL BE APPROVED AS SHORTS KNOW...

    ITS GAME OVER FOR VVUS OREX NO MONEY NO PRODUCTS NO PARTNERS

  • Report this Comment On March 25, 2014, at 12:12 PM, marp11 wrote:

    OSMELLI WRONG AGAIN yer masters getting nervous???

    BELVIQ TV ADS IMMINENT

  • Report this Comment On March 26, 2014, at 4:55 AM, marp11 wrote:

    oo ooo ooooo OOOOSMELLI

    VVUS GONE

    OREX SOO TO BE

    BELVIQ BELVIQ DTC TV IMMINENT

    300 MILL IN CASH ROW PARTNERS PIPELINE

    ISMELLI A BLOCKBUSTER COMPANY

    ITS NAME IS ARENA

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2885577, ~/Articles/ArticleHandler.aspx, 9/22/2014 6:21:04 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASD 4,527.69 -52.10 -1.14%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/22/2014 3:59 PM
GILD $105.47 Down -0.49 -0.46%
Gilead Sciences CAPS Rating: ****
OREX $4.51 Down -0.26 -5.45%
Orexigen Therapeut… CAPS Rating: **
ARNA $4.10 Down -0.06 -1.44%
Arena Pharmaceutic… CAPS Rating: **
VVUS $4.25 Up +0.09 +2.16%
VIVUS, Inc. CAPS Rating: **

Advertisement